Alembic gets FDA OK for generic VesicareSolifenacin succinate tablets 5 mg and 10 mg had a market value of approximately $967 million for the 12 months ended December 2018, according to IQVIA. Upsher-Smith hosts NASPA/Pharmacists Mutual Leadership ConferenceNewly elected leaders and association executives received education on best practices in association governance and financial management at the two-day NASPA/Pharmacists Mutual Leadership Conference. Pharmacy among industries Amazon could disrupt A CB Insights research brief outlines the four industries where Amazon's disruptive intentions are clearest. Walmart Neighborhood Market pharmacies offer FlavoRx Walmart Neighborhood Market will be offering FlavoRx's medication flavoring for patients at no additional cost. Lilly launches authorized generic of its Humalog insulin Eli Lilly’s insulin lispro injection has a list price of $137.35 per vial and $265.20 for a package of five KwikPens. Glenmark gets FDA’s blessing for generic Vesicare Solifenacin succinate tablets had a market value of roughly $942.7 million for the 12 month period ended March 2019, according to IQVIA. AbbVie gets FDA nod for Venclexta combination treatment Venclexta (venetoclax) in combination with obinutuzumab (Gazyva) provides a chemotherapy-free combination treatment option. McKesson highlights education offerings of upcoming ideaShare 2019 McKesson ideaShare 2019 will offer sessions on immunizations, diabetes care and point-of-care testing, among others. UCB gets FDA nod for Nayzilam Nayzilam is the first and only FDA-approved nasal option for treating seizure clusters. AAM submits comments at FDA public hearing on insulin biosimilars The AAM and the Biosimilars Council continue to urge the FDA to foster the development of biosimilar insulins. First Previous 521 522 523 524 525 Next Last
